Preirradiation chemotherapy (CTX) with cytoxan, Adriamycin, vincristine, and decadron (CHOD) for primary CNS lymphomas (PCNSL): initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06 (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Proc Annu Meet Am Soc Clin Oncol; 13:A485 1994. Unique Identifier : AIDSLINE ICDB/94600481
Schultz C; Scott C; Wasserman T; Fisher B; Abrams R; Sherman W; Fetell M; Nelson J; No affiliation given

Abstract: From 1988 to 1992, a prospective Phase I/II trial was carried out by the RTOG to test the tolerance and efficacy of preirradiation (RT) CHOD CTX followed by large vol, high-dose brain RT for patients (pts) with PCNSL. Fifty-four (51 evaluable) HIV-negative pts with PCNSL were entered and received 2 (19 pts) or 3 (32 pts) cycles of CHOD (6 pts with positive CSF cytology received intrathecal methotrexate in addition to CHOD). Whole brain RT to 41.4 Gy and tumor boost to 18 Gy (total dose 59.4 Gy) followed CTX. Grade 4 neutropenia during CTX developed in 28/51 pts. Worst toxicity during RT was less than or equal to grade 2 for all but 2 pts. There was 1 septic death. One pt died of encephalomalacia 3 mo following RT. All pts were potentially followed for 1 yr. Survival from registration was calculated using the Kaplan-Meier technique. Survival compared to RTOG 83-15 (IJROBP 23:9-17, 1992), which tested RT alone to 59.4 Gy, is given in a table. Age remains a powerful prognostic factor for pts with PCNSL independent of therapy. These early results suggest that the rate of 2-yr survival is increased with pre-RT CHOD CTX compared to RT alone, particularly for pts less than 60 yr of age.

Keywords: Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Brain Neoplasms/DRUG THERAPY/MORTALITY/*RADIOTHERAPY Combined Modality Therapy Cranial Irradiation Female Follow-Up Studies Human Lymphoma/DRUG THERAPY/MORTALITY/*RADIOTHERAPY Male Middle Age Prospective Studies Radiotherapy Dosage Survival Analysis Survival Rate ABSTRACT CLINICAL TRIAL, PHASE I CLINICAL TRIAL, PHASE II CLINICAL TRIAL
941030
M94A0893

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .